US Broker Ratings

SIGA Technologies Inc. (SIGA) Stock Analysis: Examining the Healthcare Player with a Strong Forward P/E of 4.18

SIGA Technologies Inc. (NASDAQ: SIGA), a prominent player in the healthcare sector, is catching the eye of investors with its compelling forward price-to-earnings (P/E) ratio of 4.18, indicating potential undervaluation..

AxoGen, Inc. (AXGN) Investor Outlook: Assessing the 83.84% Upside in the Peripheral Nerve Repair Market

AxoGen, Inc. (AXGN), a leader in the healthcare sector’s medical devices industry, is gaining investor attention due to its robust potential upside. With an impressive 83.84% potential upside based on..

Tectonic Therapeutic, Inc. (TECX) Stock Analysis: Unveiling a Potential 257.78% Upside

Tectonic Therapeutic, Inc. (NASDAQ: TECX), a promising player in the biotechnology sector, is capturing the attention of investors with its remarkable potential upside of 257.78%. This Massachusetts-based company is at..

InnovAge Holding Corp. (INNV) Stock Analysis: Navigating a 31.58% Potential Upside in Healthcare

InnovAge Holding Corp. (NASDAQ: INNV), a key player in the healthcare sector, offers a unique proposition for investors interested in the medical care facilities industry. With a market capitalization of..

Sionna Therapeutics, Inc. (SION): Investor Outlook with a 101.15% Potential Upside

Sionna Therapeutics, Inc. (NASDAQ: SION), a burgeoning player in the biotechnology sector, is capturing investors’ attention with a remarkable potential upside of 101.15%, as indicated by analyst ratings. Headquartered in..

AbCellera Biologics Inc. (ABCL) Stock Analysis: 67.90% Potential Upside Beckons Investors

AbCellera Biologics Inc. (NASDAQ: ABCL), a notable player in the biotechnology sector, has garnered significant attention from investors due to its impressive potential upside of 67.90%, as suggested by analyst..

REGENXBIO Inc. (RGNX) Stock Analysis: Navigating a Potential 244% Upside in the Biotech Sector

REGENXBIO Inc. (NASDAQ: RGNX), a clinical-stage biotechnology company, is capturing investor attention with its promising 244.10% potential upside. Specializing in gene therapies targeting genetic disorders, the firm is headquartered in..

Immunome, Inc. (IMNM) Stock Analysis: A Biotech with 117.97% Potential Upside

Immunome, Inc. (NASDAQ: IMNM), a clinical-stage biotechnology company, is making waves in the healthcare sector with its innovative cancer therapies. Based in Bothell, Washington, Immunome focuses on developing targeted treatments..

Praxis Precision Medicines, Inc (PRAX)

⚠️ No article content returned.

..

LifeMD, Inc. (LFMD) Stock Analysis: Exploring the 24.96% Potential Upside for Investors

LifeMD, Inc. (LFMD), a prominent player in the healthcare sector, presents an intriguing investment opportunity with a potential upside of 24.96%. As a direct-to-patient telehealth provider, LifeMD connects consumers with..

Enhabit, Inc. (EHAB) Stock Analysis: Navigating a 48.77% Potential Upside in the Home Health Sector

Enhabit, Inc. (EHAB), a prominent player in the healthcare sector, offers a comprehensive range of home health and hospice services across the United States. With a market capitalization of $348.89..

Bioventus Inc. (BVS) Stock Analysis: Exploring a Potential 91% Upside Amidst Healthcare Challenges

Bioventus Inc. (NASDAQ: BVS), a prominent player in the medical devices sector, is drawing attention from investors with its robust product line aimed at addressing pain relief and musculoskeletal therapies...

Keros Therapeutics (KROS) Stock Analysis: Unpacking a 66.9% Potential Upside and Breakthrough Biotech Innovations

Keros Therapeutics, Inc. (NASDAQ: KROS) presents an intriguing opportunity in the biotechnology sector, with analysts projecting a substantial 66.9% potential upside. This clinical-stage biopharmaceutical company, headquartered in Lexington, Massachusetts, focuses..

Beta Bionics, Inc. (BBNX) Stock Analysis: A 57% Potential Upside in the Healthcare Sector

Beta Bionics, Inc. (NASDAQ: BBNX), a forward-thinking company in the healthcare sector, is making waves in the medical device industry with its innovative solutions for diabetes management. With a market..

Upstream Bio (UPB) Investor Outlook: Biotechnology Stock Poised for 272% Upside

For investors seeking opportunities in the dynamic biotechnology sector, Upstream Bio, Inc. (NASDAQ: UPB) presents a compelling case with a standout potential upside of 272.03%. As a clinical-stage biotechnology company,..

Talkspace, Inc. (TALK) Stock Analysis: A 98% Potential Upside and Strategic Growth in Health Information Services

Talkspace, Inc. (NASDAQ: TALK), a trailblazer in the virtual behavioral healthcare sector, is garnering significant attention from investors with its compelling growth narrative and substantial potential upside. With a current..

Owens & Minor (OMI) Stock Analysis: Navigating Healthcare Distribution with a 19.65% Upside Potential

Owens & Minor, Inc. (NYSE: OMI) stands as a pivotal player in the healthcare distribution sector, offering a comprehensive array of products and services through its two key segments: Products..

Auna SA (AUNA) Stock Analysis: Navigating a 95.37% Upside Potential in the Healthcare Sector

Investors looking for opportunities in the healthcare sector might find Auna SA (AUNA) an intriguing prospect. This Luxembourg-based company operates hospitals and clinics across Mexico, Peru, and Colombia, offering a..

Phibro Animal Health Corporation (PAHC) Stock Analysis: Navigating a Complex Investment Landscape Amidst Impressive Revenue Growth

Phibro Animal Health Corporation (NASDAQ: PAHC) stands as a notable player in the healthcare sector, particularly within the drug manufacturing industry for specialty and generic pharmaceuticals. Based in Teaneck, New..

Xeris Biopharma Holdings (XERS): Investor Outlook with a 21.86% Potential Upside

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a prominent player in the healthcare sector, is making waves in the biotechnology industry with its innovative therapies aimed at chronic endocrine and neurological..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds